Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?

robot
Abstract generation in progress

Mirum Pharmaceuticals (MIRM) saw its shares increase by 5.1% due to higher than average trading volume, likely driven by positive developments in its phase III EXPAND study for Livmarli. Although revenue is expected to grow significantly, the consensus EPS estimate for the quarter has remained unchanged, and the stock currently holds a Zacks Rank #3 (Hold). Investors are advised to watch for trends in earnings estimate revisions to determine if the stock’s recent strength will continue.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments